Evaluation of Antihypertensive Medicines Use and Cost of Therapy on Inpatient Hypertension at IRNA-B Ward in X Hospital July-December 2010 Period

  • YUSI ANGGRIANI UNIVERSITAS PANCASILA
  • AGUS PURWANGGANA UNIVERSITAS PANCASILA
  • AHMAD SUBHAN UNIVERSITAS PANCASILA
  • RIA PUSPITA WARDHANI UNIVERSITAS PANCASILA

Abstract

The appropriate use of antihypertensive have important role for the successful of hypertension therapy. The study aims were to evaluate the use of antihypertensive medicines and cost of hypertension therapy in General, Askes and Jamkesmas inpatient at IRNA-B ward in X hospital from July to December 2010 period. Design of the study were descriptive analytical and retrospectively. Inpatients with primary hypertension and concomitant disease (hypertensive heart disease with and without congestive heart failure and hypertensive renal disease with renal failure) at IRNA-B ward in X Hospital were included to the study. The results showed that the appropriateness of the selection of antihypertensive was 87.0%. Non-formulary antihypertensive medicines were 39.3%. The lowest of medicines cost of hypertension therapy was shown in Askes inpatient. There were differences in the cost of hypertension therapy among Askes with General inpatient and Askes with Jamkesmas inpatient. There was no diference drug cost therapy between General and Jamkesmas inpatient.

References

1. Departemen Kesehatan Republik Indonesia. Pharmaceutical care untuk penyakit hipertensi. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik; 2006.1-2, 4, 7-11,13.
2. Suyono S, Waspadji S, Lesmana L, et al, editor. Buku ajar ilmu penyakit dalam. Edisi 3. Jakarta: Balai penerbit FKUI; 2001. 454-60, 462-4.
3. World Health Organization (WHO) International Society of Hypertension Statement on Management of Hypertension; 2003. 21, 1983-92.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness. treatment, and control of hypertension in The United States. 2003. 199, 206-90.
5. Nusantara Medical Centre. Pengenalan gejala stroke. faktor resiko dan tindakan preventifnya. Jakarta: Nusantara Medical Centre; 2006. 56.
6. British National Formulary. 2009. 74-9, 86-91, 98. 1029, 114-5
7. Askes asuransi kesehatan jaminan kesehatan untuk PNS dan TNI/Polri. Diambil dari http: www.askes. org. Diakses 17 Agustus 2011,
8. Departemen Kesehatan Republik Indonesia. Pedoman pelaksanaan jaminan kesehatan masyarakat (JAMKESMAS). Jakarta; 2008. 5, 6, 9.
9. Badan Pengawasan Obat dan Makananan. Informatorium obat nasional Indonesia (IONI). Jakarta: 2008. 2-142.
10. Ganiswarna SG, Setiabudy R, Suyatna FD, editor. F armakologi dan terapi. Edisi 4, Jakarta: Gaya baru: 2001. 71, 285, 296, 321, 329-36, 345, 371-89.
11. Dipiro JT, Talbert RL, Yee GC, editors. Pharmacotherap} a pathophysiologic approach. 5th Ed. New York: McGraw Hill, Medical Publishing Division; 2002.164-8, 170-4, 195, 201.
12. Todd MW. Drug use evaluation. In: Brown TR, editor. Handbook of institutional pharmacy practice. 3rd Ed. Bethesda: American Society of Hospital Pharmacist Inc; 1999. 261-2.
13. Hypertens J. European Society of Hypertension Statement on Management Hypertension; 2003. 2203-4.
14. Shargel L, Wu-pong S, B. C. Yu A. Applied biopharmaceutics and pharmacokinetics. 5th ed. United states of America: The McGraw-Hill Companies, Inc: 2005. 37-40, 571.
15. Departemen Kesehatan Republik Indonesia, Formularium edisi IV. Jakarta: Dirjen Bina Pelayanan Medik RSUP X; 2007. 8-9, 111-22.
16. Asset regulasi Kepmenkes No 302 tentang harga Obat generik. Diambil dari: http: www.pppl.depkes.go.id Diakses 14 September 2011.
Published
2012-09-30
How to Cite
ANGGRIANI, YUSI et al. Evaluation of Antihypertensive Medicines Use and Cost of Therapy on Inpatient Hypertension at IRNA-B Ward in X Hospital July-December 2010 Period. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 10, n. 2, p. 111-118, sep. 2012. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/256>. Date accessed: 25 apr. 2024.
Citation Formats
Issue
Vol 10 No 2 (2012): JIFI
Section
Articles
License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.